Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including ...
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2002-06-27
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Celgene Corporation
- Registration Number
- NCT00040391
- Locations
- 🇺🇸
Research Center, Milwaukee, Wisconsin, United States
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2002-05-31
- Last Posted Date
- 2012-07-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT00038402
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
- Conditions
- First Posted Date
- 2002-05-17
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 212
- Registration Number
- NCT00037180
- Locations
- 🇺🇸
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 158
- Registration Number
- NCT00000758
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston, Massachusetts, United States
Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 74
- Registration Number
- NCT00001569
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Fluorouracil Filtering Surgery Study (FFSS)
- Conditions
- First Posted Date
- 1999-09-24
- Last Posted Date
- 2009-09-17
- Lead Sponsor
- National Eye Institute (NEI)
- Registration Number
- NCT00000122
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.